Efficacy and safety of ribociclib (LEE011) + letrozole in elderly patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) in MONALEESA-2

被引：1
|
作者：
Sonke, G. S. [1 ,2 ]
Hart, L. L. [3 ]
Campone, M. [4 ]
Erdkamp, F. [5 ]
Janni, W. [6 ]
Verma, S. [7 ]
Villanueva, C. [8 ]
Jakobsen, E. [9 ]
Alba, E. [10 ]
Wist, E. [11 ]
Favret, A. M. [12 ]
Bachelot, T. [13 ]
Hegg, R. [14 ]
Wheatley-Price, P. [15 ]
Souami, F. [16 ]
Sutradhar, S. [17 ]
Miller, M. [18 ]
Germa, C. [18 ]
Burris, H. A. [19 ]
机构：
[1] Netherlands Canc Inst, Amsterdam, Netherlands
[2] BOOG Study Ctr, Med Oncol, Amsterdam, Netherlands
[3] Sarah Cannon Res Inst, Florida Canc Specialists & Res Inst, Hematol Oncol, Ft Myers, FL USA
[4] Rene Gauducheau Ctr Rech Cancerol, Inst Cancerol Ouest, Med Oncol, Nantes, France
[5] Zuyderland Med Ctr, Internal Med, Sittard Geleen Heerlen, Netherlands
[6] Univ Klinikum Ulm, Obstet & Gynecol, Ulm, Germany
[7] Tom Baker Canc Clin, Oncol, Calgary, AB, Canada
[8] Hosp Jean Minjoz, Univ Hosp Besancon, Med Oncol, Besancon, France
[9] Lillebaelt Hosp, Clin Oncol, Vejle, Denmark
[10] Hosp Univ Virgen de la Victoria IBIMA, Med Oncol, Malaga, Spain
[11] Oslo Univ Hosp, Oncol, Oslo, Norway
[12] Virginia Canc Specialists PC, Med Oncol, Arlington, VA USA
[13] Ctr Leon Berard, Med Oncol, Lyon, France
[14] Hosp Perola Byington, Ctr Referencia Saude Mulher, Gynecol & Obstet, Sao Paulo, Brazil
[15] Univ Ottawa, Med Oncol, Ottawa, ON, Canada
[16] Novartis Pharma AG, Basel, Switzerland
[17] Novartis Pharma SAS, Paris, France
[18] Novartis Pharmaceut, E Hanover, NJ USA
[19] Sarah Cannon Res Inst, Clin Operat, Nashville, TN USA
来源：
EUROPEAN JOURNAL OF CANCER | 2017年 / 72卷
关键词：
D O I：
10.1016/S0959-8049(17)30091-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2LBA
引用
收藏
页码：S1 / S2
页数：3
相关论文
共 50 条
  • [1] First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 safety results.
    Janni, Wolfgang
    Burris, Howard A.
    Blackwell, Kimberly L.
    Hart, Lowell L.
    Chan, Arlene
    Nusch, Arnd
    Burdaeva, Olga Nikolaevna
    Alba, Emilio
    Yardley, Denise A.
    Bachelot, Thomas Denis
    Gil, Miguel J. Gil
    Richards, Donald A.
    Sparano, Joseph A.
    Kattan, Joseph Gergi
    Bourgeois, Hugues Pierre
    El Karak, Fadi Rafic
    Ramaswamy, Bhuvaneswari
    Sutradhar, Santosh C.
    Miller, Michelle Kristine
    Conte, Pier Franco
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] First-line ribociclib (RIB) plus letrozole (LET) in hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 biomarker analyses
    Hortobagyi, Gabriel N.
    Paluch-Shimon, Shani
    Petrakova, Katarina
    Villanueva, Cristian
    Chan, Arlene
    Nusch, Arnd
    Yap, Yoon Sim
    Hart, Lowell
    Favret, Anne
    Marschner, Norbert
    Sonke, Gabe S.
    Ohnstad, Hege Oma
    Arteaga, Carlos
    Su, Fei
    He, Wei
    Miller, Michelle Kristine
    Stemmer, Salomon M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib plus letrozole in hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC).
    Hortobagyi, Gabriel N.
    Stemmer, Salomon M.
    Burris, Howard A.
    Yap, Yoon Sim
    Sonke, Gabe S.
    Paluch-Shimon, Shani
    Campone, Mario
    Petrakova, Katarina
    Blackwell, Kimberly L.
    Winer, Eric P.
    Janni, Wolfgang
    Verma, Sunil
    Conte, Pier Franco
    Arteaga, Carlos L.
    Cameron, David A.
    Xuan, Fengjuan
    Miller, Michelle Kristine
    Germa, Caroline
    Hirawat, Samit
    O'Shaughnessy, Joyce
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial
    Sonke, Gabe S.
    Hart, Lowell L.
    Campone, Mario
    Erdkamp, Frans
    Janni, Wolfgang
    Verma, Sunil
    Villanueva, Cristian
    Jakobsen, Erik
    Alba, Emilio
    Wist, Erik
    Favret, Anne M.
    Bachelot, Thomas
    Hegg, Roberto
    Wheatley-Price, Paul
    Souami, Farida
    Sutradhar, Santosh
    Miller, Michelle
    Germa, Caroline
    Burris, Howard A.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 167 (03) : 659 - 669
  • [5] Ribociclib (LEE011) and letrozole in estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced breast cancer (aBC): Phase Ib safety, preliminary efficacy and molecular analysis.
    Juric, Dejan
    Munster, Pamela N.
    Campone, Mario
    Ismail-Khan, Roohi
    Garcia-Estevez, Laura
    Hamilton, Erika Paige
    Becerra, Carlos
    De Boer, Richard H.
    Hui, Rina
    Goncalves, Anthony
    Wang, Yingbo
    Dhuria, Shyeilla V.
    Kalimi, Ghulam H.
    Lorenc, Karen Cristina Rodriguez
    Mayer, Ingrid A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC)
    Hortobagyi, G. N.
    Stemmer, S. M.
    Burris, H. A.
    Yap, Y. S.
    Sonke, G. S.
    Paluch-Shimon, S.
    Campone, M.
    Blackwell, K.
    Andre, F.
    Winer, E. P.
    Janni, W.
    Verma, S.
    Conte, P.
    Arteaga, C. L.
    Cameron, D.
    Xuan, F.
    Souami, F.
    Miller, M.
    Germa, C.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [7] Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial
    Gabe S. Sonke
    Lowell L. Hart
    Mario Campone
    Frans Erdkamp
    Wolfgang Janni
    Sunil Verma
    Cristian Villanueva
    Erik Jakobsen
    Emilio Alba
    Erik Wist
    Anne M. Favret
    Thomas Bachelot
    Roberto Hegg
    Paul Wheatley-Price
    Farida Souami
    Santosh Sutradhar
    Michelle Miller
    Caroline Germa
    Howard A. Burris
    Breast Cancer Research and Treatment, 2018, 167 : 659 - 669
  • [8] Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib 1 letrozole in hormone receptor-positive (HR1), HER2-negative (HER2-) advanced breast cancer (ABC)
    Spazzapan, S.
    Conte, P.
    Simoncini, E.
    Campone, M.
    Miller, M.
    Sonke, G.
    ANNALS OF ONCOLOGY, 2017, 28
  • [9] Ribociclib plus letrozole vs placebo plus letrozole in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) and a high disease burden
    Verma, S.
    Gil-Gil, M.
    Hegg, R.
    Wheatley-Price, P.
    Kattan, J.
    Bourgeois, H.
    Sutradhar, S.
    Miller, M.
    Campone, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [10] Ribociclib (RIB) plus endocrine therapy (ET) in Japanese women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC)
    Masuda, N.
    Noguchi, S.
    Ishikawa, T.
    Aruga, T.
    Kim, S. J.
    Toyama, T.
    Saeki, T.
    Saito, M.
    Yamanaka, T.
    Watanabe, J.
    Nakamura, S.
    Takahashi, M.
    Inoue, K.
    Gounaris, I.
    Han, Y.
    Samant, T. S.
    Gazdoiu, M.
    Ito, Y.
    ANNALS OF ONCOLOGY, 2018, 29
12345